JP2012507302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507302A5 JP2012507302A5 JP2011534864A JP2011534864A JP2012507302A5 JP 2012507302 A5 JP2012507302 A5 JP 2012507302A5 JP 2011534864 A JP2011534864 A JP 2011534864A JP 2011534864 A JP2011534864 A JP 2011534864A JP 2012507302 A5 JP2012507302 A5 JP 2012507302A5
- Authority
- JP
- Japan
- Prior art keywords
- rsv
- seq
- virus
- nucleotide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 271
- 241000700605 Viruses Species 0.000 claims description 190
- 239000002773 nucleotide Substances 0.000 claims description 189
- 125000003729 nucleotide group Chemical group 0.000 claims description 189
- 230000002238 attenuated effect Effects 0.000 claims description 158
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- 150000001413 amino acids Chemical group 0.000 claims description 107
- 235000018102 proteins Nutrition 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 230000003612 virological effect Effects 0.000 claims description 71
- 101150082239 G gene Proteins 0.000 claims description 66
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 23
- 101150034814 F gene Proteins 0.000 claims description 22
- 101150062031 L gene Proteins 0.000 claims description 22
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 20
- 239000004471 Glycine Substances 0.000 claims description 17
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 17
- 235000013922 glutamic acid Nutrition 0.000 claims description 16
- 239000004220 glutamic acid Substances 0.000 claims description 16
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 12
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 101710104359 F protein Proteins 0.000 description 181
- 230000035772 mutation Effects 0.000 description 158
- 235000001014 amino acid Nutrition 0.000 description 127
- 229940024606 amino acid Drugs 0.000 description 116
- 125000003275 alpha amino acid group Chemical group 0.000 description 56
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 47
- 150000007523 nucleic acids Chemical class 0.000 description 38
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 37
- 102000039446 nucleic acids Human genes 0.000 description 33
- 108020004707 nucleic acids Proteins 0.000 description 33
- 238000000034 method Methods 0.000 description 32
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 30
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 26
- 229960005486 vaccine Drugs 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 210000004072 lung Anatomy 0.000 description 25
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 208000015181 infectious disease Diseases 0.000 description 23
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 22
- 101710128560 Initiator protein NS1 Proteins 0.000 description 22
- 101710144127 Non-structural protein 1 Proteins 0.000 description 22
- 108700026244 Open Reading Frames Proteins 0.000 description 22
- 108091006027 G proteins Proteins 0.000 description 21
- 108091000058 GTP-Binding Proteins 0.000 description 21
- 238000010240 RT-PCR analysis Methods 0.000 description 21
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 20
- 101710144128 Non-structural protein 2 Proteins 0.000 description 20
- 101710199667 Nuclear export protein Proteins 0.000 description 20
- 229920002477 rna polymer Polymers 0.000 description 20
- 230000003321 amplification Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 108020004705 Codon Proteins 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 16
- 230000010076 replication Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 241000282552 Chlorocebus aethiops Species 0.000 description 14
- 241000282412 Homo Species 0.000 description 14
- 238000012300 Sequence Analysis Methods 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 230000028993 immune response Effects 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 13
- 102000054765 polymorphisms of proteins Human genes 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- 241000144282 Sigmodon Species 0.000 description 11
- 241000144290 Sigmodon hispidus Species 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000012634 fragment Substances 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 102000053602 DNA Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 241000711920 Human orthopneumovirus Species 0.000 description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
- 101150095629 NS2 gene Proteins 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 102000030782 GTP binding Human genes 0.000 description 8
- 101150033828 NS1 gene Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000001331 nose Anatomy 0.000 description 7
- 238000002864 sequence alignment Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 5
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 5
- 102100024407 Jouberin Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000035415 Reinfection Diseases 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010006448 Bronchiolitis Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000724205 Rice stripe tenuivirus Species 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- 238000011809 primate model Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 102220044516 rs202197835 Human genes 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 229940124679 RSV vaccine Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000030500 lower respiratory tract disease Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102200105394 rs1060501198 Human genes 0.000 description 2
- 102220317346 rs145871499 Human genes 0.000 description 2
- 102220268734 rs1555338682 Human genes 0.000 description 2
- 102200024306 rs35193847 Human genes 0.000 description 2
- 102220227441 rs899935666 Human genes 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001944 turbinate Anatomy 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 208000011479 upper respiratory tract disease Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000007485 viral shedding Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CGMWMYHEKGCISN-UHFFFAOYSA-N (2-chloro-6-fluorophenyl)hydrazine Chemical compound NNC1=C(F)C=CC=C1Cl CGMWMYHEKGCISN-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710104895 DNA replication protein 17 Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000686777 Escherichia phage T7 T7 RNA polymerase Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101710189078 Helicase Proteins 0.000 description 1
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102100028467 Perforin-1 Human genes 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 1
- 102100037593 Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta Human genes 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000002365 Viral Bronchiolitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19832708P | 2008-11-05 | 2008-11-05 | |
| US61/198,327 | 2008-11-05 | ||
| PCT/US2009/063024 WO2010053883A1 (en) | 2008-11-05 | 2009-11-03 | Live, attentuated respiratory syncytial virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011171459A Division JP5743794B2 (ja) | 2008-11-05 | 2011-08-05 | 生弱毒化呼吸器合胞体ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507302A JP2012507302A (ja) | 2012-03-29 |
| JP2012507302A5 true JP2012507302A5 (OSRAM) | 2012-05-17 |
| JP5016731B2 JP5016731B2 (ja) | 2012-09-05 |
Family
ID=41527812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534864A Expired - Fee Related JP5016731B2 (ja) | 2008-11-05 | 2009-11-03 | 生弱毒化呼吸器合胞体ウイルス |
| JP2011171459A Expired - Fee Related JP5743794B2 (ja) | 2008-11-05 | 2011-08-05 | 生弱毒化呼吸器合胞体ウイルス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011171459A Expired - Fee Related JP5743794B2 (ja) | 2008-11-05 | 2011-08-05 | 生弱毒化呼吸器合胞体ウイルス |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9011876B2 (OSRAM) |
| EP (1) | EP2346990B1 (OSRAM) |
| JP (2) | JP5016731B2 (OSRAM) |
| KR (1) | KR20110063863A (OSRAM) |
| CN (1) | CN102272295A (OSRAM) |
| AU (1) | AU2009311287C1 (OSRAM) |
| BR (1) | BRPI0921424A2 (OSRAM) |
| CA (1) | CA2742086A1 (OSRAM) |
| CL (1) | CL2011000999A1 (OSRAM) |
| CO (1) | CO6362047A2 (OSRAM) |
| EC (1) | ECSP11011033A (OSRAM) |
| IL (1) | IL212437A0 (OSRAM) |
| MA (1) | MA32878B1 (OSRAM) |
| MX (1) | MX2011004719A (OSRAM) |
| PE (1) | PE20110394A1 (OSRAM) |
| RU (1) | RU2011122615A (OSRAM) |
| TN (1) | TN2011000182A1 (OSRAM) |
| WO (1) | WO2010053883A1 (OSRAM) |
| ZA (1) | ZA201103259B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2346990B1 (en) * | 2008-11-05 | 2016-01-06 | Merck Sharp & Dohme Corp. | Live, attentuated respiratory syncytial virus |
| WO2013026054A2 (en) * | 2011-08-18 | 2013-02-21 | Axella Solutions, Llc | Production of infectious rna viruses in yeast |
| EP2752199A4 (en) | 2011-08-29 | 2015-04-29 | Univ Tokushima | RSV MUCOSA VACCINE |
| AU2014214763B2 (en) * | 2013-02-08 | 2020-02-27 | The Research Foundation For The State University Of New York | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
| EP3798310A1 (en) * | 2013-03-14 | 2021-03-31 | Emory University | Recombinant rsv with silent mutations, vaccines, and methods related thereto |
| US10429129B2 (en) | 2013-10-16 | 2019-10-01 | Merck Sharp & Dohme Corp. | Method of microwave vacuum drying spherical-shaped pellets of biological materials |
| CA2926696A1 (en) | 2013-10-16 | 2015-04-23 | Merck Sharp & Dohme Corp | Thermostable respiratory synctial virus (rsv) vaccine compositions |
| WO2017030997A1 (en) * | 2015-08-14 | 2017-02-23 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having altered ns1 protein function and related materials and methods |
| US11235050B2 (en) | 2015-10-29 | 2022-02-01 | Emory University | Chimeric RSV, immunogenic compositions, and methods of use |
| WO2018057950A1 (en) | 2016-09-23 | 2018-03-29 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| AU2018331467A1 (en) * | 2017-09-15 | 2020-04-30 | Ohio State Innovation Foundation | Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (RSV) infections |
| WO2025106787A1 (en) * | 2023-11-17 | 2025-05-22 | Sanofi Pasteur Inc. | Trehalose vaccine formulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2250883A1 (en) * | 1996-04-04 | 1997-10-16 | The Regents Of The University Of Michigan | Attenuated respiratory syncytial virus |
| EP1064358A2 (en) | 1998-03-26 | 2001-01-03 | American Cyanamid Company | Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b |
| EP1287152B1 (en) | 1999-07-09 | 2008-12-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Human-bovine chimeric respiratory syncytial virus vaccines |
| US20050176130A1 (en) | 2002-09-27 | 2005-08-11 | Medimmune Vaccines, Inc. | Functional mutations in respiratory syncytial virus |
| JP4783726B2 (ja) * | 2003-03-28 | 2011-09-28 | メディミューン，エルエルシー | 呼吸器合胞体ウイルスサブグループｂ株９３２０に関連する組成物および方法 |
| CN101646768A (zh) * | 2007-02-07 | 2010-02-10 | 生物载体株式会社 | 减毒负链rna病毒 |
| EP2346990B1 (en) * | 2008-11-05 | 2016-01-06 | Merck Sharp & Dohme Corp. | Live, attentuated respiratory syncytial virus |
-
2009
- 2009-11-03 EP EP09748199.8A patent/EP2346990B1/en active Active
- 2009-11-03 BR BRPI0921424A patent/BRPI0921424A2/pt not_active IP Right Cessation
- 2009-11-03 CA CA2742086A patent/CA2742086A1/en not_active Abandoned
- 2009-11-03 KR KR1020117010304A patent/KR20110063863A/ko not_active Ceased
- 2009-11-03 JP JP2011534864A patent/JP5016731B2/ja not_active Expired - Fee Related
- 2009-11-03 RU RU2011122615/10A patent/RU2011122615A/ru not_active Application Discontinuation
- 2009-11-03 CN CN2009801537266A patent/CN102272295A/zh active Pending
- 2009-11-03 WO PCT/US2009/063024 patent/WO2010053883A1/en not_active Ceased
- 2009-11-03 AU AU2009311287A patent/AU2009311287C1/en not_active Ceased
- 2009-11-03 US US13/127,647 patent/US9011876B2/en active Active
- 2009-11-03 PE PE2011000971A patent/PE20110394A1/es not_active Application Discontinuation
- 2009-11-03 MX MX2011004719A patent/MX2011004719A/es unknown
-
2011
- 2011-04-17 IL IL212437A patent/IL212437A0/en unknown
- 2011-04-19 TN TN2011000182A patent/TN2011000182A1/fr unknown
- 2011-05-04 CL CL2011000999A patent/CL2011000999A1/es unknown
- 2011-05-05 EC EC2011011033A patent/ECSP11011033A/es unknown
- 2011-05-05 ZA ZA2011/03259A patent/ZA201103259B/en unknown
- 2011-05-12 CO CO11058596A patent/CO6362047A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33913A patent/MA32878B1/fr unknown
- 2011-08-05 JP JP2011171459A patent/JP5743794B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5016731B2 (ja) | 生弱毒化呼吸器合胞体ウイルス | |
| JP2012507302A5 (OSRAM) | ||
| JP2011250798A5 (OSRAM) | ||
| AU2021218112B2 (en) | Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes | |
| US10980872B2 (en) | Genetically stable live attenuated respiratory syncytial virus vaccine and its production | |
| US10329584B2 (en) | Modified Sendai virus vaccine and imaging vector | |
| HK40057493A (en) | Genetically stable live attenuated respiratory syncytial virus vaccine and its production |